News

Baby gut bacteria fails to mature normally with CF, study finds

Young children with cystic fibrosis (CF) have less mature gut bacterial growth over time than do their typically developing peers, according to a new U.S. study. “Our findings demonstrate that the gut microbiota of infants with CF fails to undergo typical developmental maturation, instead remaining entrenched in a transitional-like…

Orkambi shows benefits for children with cystic fibrosis

Among children with cystic fibrosis (CF), starting the approved oral therapy Orkambi (ivacaftor/lumacaftor) led to favorable changes in lung function and structure after one year, a real-world study shows. Improvements were seen in markers of small airway function and structural changes, including the lung clearance index (LCI), indicating…

Risk of cardiovascular disease may rise for adults using Kaftrio/Trikafta

In adults with cystic fibrosis (CF), six of months treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) led to lower levels of biomarkers of inflammation, but higher blood levels of fat-like molecules considered to be cardiovascular risk factors, according to a recent study in Italy. While highly effective, the triple-combination therapy — available…

Investment to support CMTX-101 testing for chronic lung infections

Clarametyx Biosciences has announced an investment from Kineticos AMR Accelerator (KAMRA) Fund to support the development of CMTX-101, a non-antibiotic treatment candidate for persistent bacterial lung infections in people with cystic fibrosis (CF). This investment, which extends the company’s $33-million financing completed last year, will contribute…